7150-46-1

Usage

InChI:InChI=1/C11H13N3O2/c1-13(2)7-8-6-12-9-4-3-5-10(11(8)9)14(15)16/h3-6,12H,7H2,1-2H3

Upstream product

• 4769-97-5 4-nitro-1H-indoIe 
• 33797-51-2 eschenmoser's salt 
• 50-00-0 formaldehyd 
• 124-40-3 dimethyl amine 
• 10553-11-4 4-nitro-1H-indole-3-carbaldehyde 
• 109175-08-8 methyl 4-nitro-1H-indole-3-carboxylate 
• 30438-74-5 N-(chloromethyl)dimethylamine 
• 51-80-9 bis-(dimethylamino)methane 
• 87-52-5 3-(Dimethylaminomethyl)indole 
• 942-24-5 3-methoxycarbonylindole 
• 115118-93-9 ethyl N-(2-methyl-3-nitrophenyl)formimidate 
• 603-83-8 3-nitro-o-tolylamine 

Downstream Products

• 4769-97-5 4-nitro-1H-indoIe 
• 4770-06-3 4-nitroindole-3-acetonitrile 
• 2519-61-1 4-chloroindole-3-acetic acid 
• 89434-03-7 4-fluoroindole-3-acetic acid 
• 89245-41-0 4-bromo-3-indoleacetic acid 
• 89434-02-6 4-iodo-3-indoleacetic acid 
• 880086-79-3 diethyl 2,2'-(4-nitro-1H-indole-1,3-diyl)diacetate 
• 5698-18-0 3,4,5,6-tetrahydro-1H-azepino[4,3,2-cd]indole 
• 314746-03-7 6-[4-[[(2-biphenyl)carbonyl]amino]benzoyl]-3,4,5,6-tetrahydro-1H-azepino[4,3,2-cd]indole 
• 90162-68-8 (S)-3-Methyl-2-(toluene-4-sulfonylamino)-butyric acid (S)-2-tert-butoxycarbonylamino-3-(4-nitro-1H-indol-3-yl)-propyl ester 
• 90162-69-9 (S)-3-Methyl-2-(toluene-4-sulfonylamino)-butyric acid (R)-2-tert-butoxycarbonylamino-3-(4-nitro-1H-indol-3-yl)-propyl ester 
• 84590-48-7 (-)-epi-indolactam V 
• 84590-48-7 (+)-indolactam V 
• 110595-80-7 Benzoic acid (S)-2-tert-butoxycarbonylamino-3-(4-nitro-1H-indol-3-yl)-propyl ester 

Relevant academic research and scientific papers

Synthesis and NMR characteristics of N-acetyl-4-nitro, N-acetyl-5-nitro, N-acetyl-6-nitro and N-acetyl-7-nitrotryptophan methyl esters

N-acetyl-4-nitrotryptophan methyl ester (2), N-acetyl-5-nitrotryptophan methyl ester (3), N-acetyl-6-nitrotryptophan methyl ester (4) and N-acetyl-7-nitrotryptophan methyl ester (5) were synthesized through a modified malonic ester reaction of the appropriate nitrogramine analogs followed by methylation with BF3-methanol. Assignments of the 1H and 13C NMR chemical shifts were made using a combination of 1H-1H COSY, 1H-13C HETCOR and 1H-13C selective INEPT experiments. Copyright

TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula (I): (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, R6, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, T, U, V, W, X, Y, Z, R4, R5a?, R5b/su

TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, J, K, T, U, V, W, X, Y, Z, R4, R5a, R5b, R5c, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Indoloazepines as vasopressin receptor antagonists

The invention is directed to tricyclic indoloazepine compounds useful as vasopressin receptor antagonists, pharmaceutical compositions comprising the compounds of the present invention and methods of treating conditions involving increased vascular resist

Protein Kinase C Modulators. Indolactams. 1. Efficient and Flexible Routes for the Preparation of (-)-Indolactam V for Use in the Synthesis of Analogs

Three syntheses of the protein kinase C activator, (-)-indolactam V, are described and are compared for their potential utility in the preparation of ILV analogs.In one route the 4-amino functionality is introduced regiospecifically during the constructio

A SYNTHESIS METHOD OF INDOLE-3-METHANAMINE AND/OR GRAMINE FROM INDOLE-3-CARBOXALDEHYDE, AND ITS APPLICATION FOR THE SYNTHESES OF BRASSININ, ITS 4-SUBSTITUTED ANALOGS, AND 1,3,4,5-TETRAHYDROPYRROLOQUINOLINE

Simple conversion method of indole-3-carboxaldehyde into gramine and/or indole-3-methanamine was developed.The present method realized short step syntheses of brassinin, 4-iodo-, methoxy-, 4-methoxy, and 4-nitrobrassinin, 4-methoxyindole-3-acetonitrile, and 1,3,4,5-tetrahydropyrroloquinoline.